[HTML][HTML] Cell-of-origin targeted drug repurposing for triple-negative and inflammatory breast carcinoma with HDAC and HSP90 inhibitors combined with niclosamide
Simple Summary The human body is composed of hundreds of different normal cell types.
Some of the important and unique features of these normal cell types are inherited by the …
Some of the important and unique features of these normal cell types are inherited by the …
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide.
U Bhattacharya, M Kamran, M Manai… - …, 2023 - search.ebscohost.com
Abstract Simple Summary: The human body is composed of hundreds of different normal
cell types. Some of the important and unique features of these normal cell types are …
cell types. Some of the important and unique features of these normal cell types are …
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
U Bhattacharya, M Kamran, M Manai… - …, 2023 - pubmed.ncbi.nlm.nih.gov
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
U Bhattacharya, M Kamran, M Manai, M Cristofanilli… - …, 2023 - search.proquest.com
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
[PDF][PDF] Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with …
U Bhattacharya, M Kamran, M Manai… - Cancer, 2010 - pdfs.semanticscholar.org
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
[HTML][HTML] Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with …
U Bhattacharya, M Kamran, M Manai, M Cristofanilli… - Cancers, 2023 - ncbi.nlm.nih.gov
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
[PDF][PDF] Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with …
U Bhattacharya, M Kamran, M Manai, M Cristofanilli… - Cancer, 2010 - researchgate.net
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide.
U Bhattacharya, M Kamran, M Manai, M Cristofanilli… - Cancers, 2023 - europepmc.org
We recently identified a cell-of-origin-specific mRNA signature associated with metastasis
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …
and poor outcome in triple-negative carcinoma (TNBC). This TNBC cell-of-origin signature is …